

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

USSN : 10/009,620

Applicant: Wiegand, S. J.

Date Filed: December 11, 2001

Title: Methods of Imaging and Targeting
Tumor Vasculature

Examiner: Not yet known

Group Art Unit: 3736

February 6, 2003

RECEIVED

FEB 20 2003

U.S. PATENT DOCUMENTS

TECHNOLOGY CENTER R3700

Examiner Initials	Patent Number	Issue Date	Publication Number	Publication Date	Name
/EW/					

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class/ Date Subclass	Translation Yes No
/EW/	WO/99 40947	08/19/99	PCT		
	WO/00 18439	04/06/00	PCT		

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

Maisonpierre, PC, et al., 1997, "Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis", Science 277:55-60

Kirsch, JE, 1991, "Basic principles of magnetic resonance contrast agents", Top Magn Reson Imaging 3:1-18

Wallis, F. and Gilbert, FJ, 1999, J R, "Magnetic resonance imaging in oncology: an overview", Coll Surg Edinb 44:117-125

Schiepers, C. and Hoh, CK, 1998, "Positron emission tomography as a diagnostic tool in oncology", Eur Radiol 8:1481-1494

Ferrand, SK, et al., 1999, "What is new in nuclear medicine imaging?", Surg Oncol Clin N Am 8:185-204

/EW/

Asahara, T. et al., 1998, "Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization", *Circ Res* 83(3):233-240.

Lin, P., et al., 1998, "Anti-angiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2", *PNAS USA* 95:8829-8834.

Tanaka, S., et al., 1999, "Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma", *J Clin Invest* 103(3):341-345.

Molema, G., et al., 2000, "The use of bispecific antibodies in tumor cell and tumor vasculature directed immunotherapy", *J Control Release* 64 (1-3):229-239.

Berns, A., 1999, "Mouse model for cancer at center stage - AACR special meeting: Cancer biology and the mutant mouse: New methods, new models, new insights, Keystone, Colorado, USA 31 January - 5 February 1999", *Trends in Genetics* 15(5):177.

Lauren, J., et al., 1998, "Is angiopoietin-2 necessary for the initiation of angiogenesis?", *Am J Path* 153(5):1333-1339.

Stratmann, A., et al., 1998, "Cell type-specific of expression of angiopoietin-2 suggests a role in glioblastoma angiogenesis", *Am J Path* 153(5):1459-1466.

Wong, MP., et al., 1999, "Down-regulated angiopoietin-1/tie2 receptor pathway and enhanced expression of vascular endothelial growth factor and angiopoietin-2 in non-small cell lung carcinoma", *Proc Am Assoc Canc Res Annual* 40:556.

Ding, H. et al., 1999, "Expression and hypoxic regulation of angiopoietins and its receptors in human astrocytoma cell lines and tumor specimens", *Proc Am Assoc Canc Res Annual* 40:556.

Chan, ASY, et al., 1999, "Angiopoietin-2 and VEGF co-express in the accelerated phase of angiogenesis during anaplastic progression of gliomas", *Proc Am Assoc Canc Res Annual* 40:414.

Fujikawa, K., et al., 1998, "Expression of angiopoietin-1, angiopoietin-2, tie-1 and tie-2 in breast cancer", *Blood* 92(10, Suppl 1, Part1-2, page 174A

Holash, J, et al., 1999, "Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF", *Science*, 284(5422):1994-1998.

Zagzag, D, et al., 1999, "In situ expression of angiopoietins in astrocytoma identifies angiopoietin-2 as an early marker of tumor angiogenesis", *Exp Neuro* 159(2):391-400.

Yoshida, Y., et al., 1999, "Expression of angiostatic factors in colorectal cancer", *Int J Oncol* 15(6):1221-1225.

/EW/ Holash, J., et al., 1999, "New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF", *Oncogene*, 19(38):5356-5362.

/EW/ Ijland, SAJ, et al., 1999, "Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines", *Melanoma Res* 9(5):445-450.

/EW/ Theis, H., et al., 1999, "Role of VEGF, angiopoietins and their receptors in angiogenesis of renal cell carcinoma", *J Am Soc Neph* 10, Program and Abstract Issue:186A.

EXAMINER
CONSIDERED

DATE

/Ellsworth Weatherby/

08/29/2007

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By: Linda O. Palladino

Linda O. Palladino
Reg. No. 45,636
Agent for Applicants
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400